Methylfolate vs Folic Acid — the MTHFR question, compared honestly
For neural-tube defect prevention in pregnancy, synthetic folic acid has decades of trial and population-level evidence behind it and remains the standard recommendation. For most other uses, the methylfolate-vs-folic-acid choice is overstated by the supplement industry — both raise red-cell folate, and the practical case for L-5-MTHF is narrower than direct-to-consumer marketing implies.
Quick verdict
| Goal | Better choice | Why |
|---|---|---|
| Preconception / pregnancy (neural-tube defect prevention) | Folic acid | 400–800 mcg/day folic acid is the form trialed and used in every public-health intervention; this is the evidence base. |
| Adjunct in major depression (with SSRI) | L-Methylfolate (15 mg) | The Deplin protocol uses 15 mg L-methylfolate; trial evidence for adjunctive use in inadequate responders is stronger for this form. |
| Homozygous MTHFR C677T with elevated homocysteine | L-Methylfolate (mild edge) | Theoretical bypass of reduced MTHFR enzyme activity; in practice both forms work but methylfolate avoids unmetabolized folic acid accumulation. |
| Generic folate repletion in adults | Either works | Both correct biochemical deficiency at 400–800 mcg; the gain from methylfolate is small. |
| Cost | Folic acid | Folic acid is roughly 5–10× cheaper than equivalent methylfolate. |
| Risk of masking B12 deficiency | Tie | Both can correct anemia without correcting neurologic damage; high-dose folate of either form requires B12 status confirmation. |
How they actually work
Folic acid — synthetic provitamin form
Folic acid is a fully oxidised synthetic form of folate not found in nature. It is converted in the liver and intestinal wall to dihydrofolate and then tetrahydrofolate via dihydrofolate reductase (DHFR) before entering the one-carbon metabolism pool. The synthetic form was selected for the original public-health programs because it is exceptionally stable, cheap, and well-absorbed (about 85% bioavailable from supplements, higher than natural food folate).
L-Methylfolate (5-MTHF) — the active circulating form
L-Methylfolate is the biologically active form of folate that circulates in plasma and donates methyl groups in the homocysteine remethylation reaction. By taking it directly, you bypass several enzymatic steps including the MTHFR-catalysed reduction of 5,10-methylene-THF to 5-MTHF. Calcium L-5-methyltetrahydrofolate (Metafolin / Quatrefolic) is the most-studied branded form.
Neural-tube defects — folic acid is the evidence base
The 1991 MRC Vitamin Study and 1992 Czeizel-Dudás trials, plus mandatory fortification of grain products since 1998 in the US, used and use folic acid. The reduction in neural-tube defects from 400 mcg/day folic acid is established. Methylfolate has not been trialed in this indication at the same scale and is not the recommended form for preconception or first-trimester pregnancy supplementation. The supplement-industry argument that "methylfolate is safer in MTHFR carriers during pregnancy" is not supported by clinical outcome data — folic acid prevents neural-tube defects in MTHFR carriers and non-carriers.
The MTHFR question — overstated
The MTHFR C677T polymorphism (and the less-relevant A1298C) reduces enzyme activity. About 10–15% of populations of European ancestry are homozygous (TT). In TT individuals, fasting homocysteine is mildly elevated and red-cell folate is mildly lower than CC individuals at the same intake. None of this confers meaningful clinical disease risk in well-nourished populations, and folic acid supplementation corrects the biochemistry. The direct-to-consumer "MTHFR testing" industry oversells the clinical relevance of these variants by several orders of magnitude. The American College of Medical Genetics and American Heart Association both explicitly advise against routine MTHFR testing.
Adjunctive use in depression — the clearest methylfolate case
The Deplin (15 mg L-methylfolate) protocol has trial evidence as an adjunct in patients with major depressive disorder who have inadequate response to SSRIs. The 7.5 mg dose performs worse than 15 mg. This is not a generic mood supplement — the trial population was specifically inadequate-responders on antidepressants, not first-line treatment of depression in unmedicated adults.
Unmetabolized folic acid — the theoretical concern
At doses above roughly 400 mcg/day, particularly in older adults and those with low B12, some folic acid escapes liver conversion and circulates as unmetabolized folic acid (UMFA). Observational data have flagged UMFA correlations with various outcomes (some cancer markers, immune-cell effects) but causation is not established. The most-cited UMFA concerns have not translated into adverse outcomes in fortified populations. Methylfolate at equivalent doses does not produce UMFA. For people taking multi-mg doses long-term, this is the theoretical argument for methylfolate.
Dose, form, and timing
Folic acid: 400–800 mcg/day. Cheap, stable, well-absorbed. The form in nearly all prenatal vitamins and standard B-complex products.
L-Methylfolate (Metafolin / Quatrefolic / calcium L-5-MTHF): 400–800 mcg/day for repletion; 15 mg in the depression-adjunct protocol. Stored away from heat and moisture. More expensive per dose.
Safety
Both forms can mask the hematologic signature of B12 deficiency (megaloblastic anemia) while neurologic damage progresses. Check B12 alongside folate before chronic supplementation, particularly in adults over 50 and vegans. Methylfolate at the 15 mg depression dose is occasionally associated with agitation, anxiety, or insomnia — uncommon but worth knowing. Folic acid in fortified diets is generally well-tolerated.
What we'd actually buy
For pregnancy planning and first trimester: a standard prenatal with 400–600 mcg folic acid (or the methylfolate version if it's already in your prenatal — both work for this dose range). For generic B-complex use: whichever form is in the product you already have. For depression adjunct under prescriber care: 15 mg L-methylfolate (Deplin or generic equivalent). Skip the consumer "MTHFR panel" sold direct-to-consumer.
Sources
- MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–137. PMID: 1677062
- Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832–1835. PMID: 1307234
- Papakostas GI, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267–1274. PMID: 23212058
- Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto). 2017;57(5):142–149. PMID: 28326653
- Pietrzik K, et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010;49(8):535–548. PMID: 20608755
- Hickey SE, et al; ACMG. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153–156. PMID: 23288205